Biosimilars are expected to offer the same treatment benefits as the corresponding original biologic, but at a lower cost. As a result, the biosimilars market is highly cost competitive with drug prices having a direct impact on market share and return on investment.

Companies developing and manufacturing biosimilars face several challenges such as the need to accelerate progress, optimize production workflows to maximize cost efficiencies, and ensure comparable quality and efficacy with the reference product. They must also establish strategies for extensive cell line testing and characterization, safety testing, and protein comparability analysis. Given these imperatives, the biosimilar industry requires manufacturing strategies to compress timelines, improve efficiency, and increase agility.

MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany, empowers you to optimize and streamline your development and manufacturing processes. As you are racing to develop your biosimilar, we will help you meet your goals for speed, efficiency, and agility.

We offer a convergent end-to-end portfolio of advanced, closed processing-ready technologies with extensive documentation for upstream and downstream operations, process analytical technologies (PAT), data analytics, automation and control software, contract testing and analytical development services, non-GMP environment labs, and CTDMO services for mAbs, high potency active pharmaceutical ingredients (HPAPIs), antibody drug conjugates (ADCs), mRNA, and lipid nanoparticle (LNP) formulation.

Browse our capabilities now.

MilliporeSigma | Life Science Products & Service Solutions (sigmaaldrich.com)